Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,037

The DOI matches its Crossref record.

Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial

Prorok, Philip C., Andriole, Gerald L., Bresalier, Robert S., Buys, Saundra S., Chia, David, David Crawford, E., Fogel, Ronald, Gelmann, Edward P., Gilbert, Fred, Hasson, Marsha A., Hayes, Richard B., Johnson, Christine Cole, Mandel, Jack S., Oberman, Albert, O'Brien, Barbara, Oken, Martin M., Rafla, Sameer, Reding, Douglas, Rutt, Wilmer, Weissfeld, Joel L., Yokochi, Lance, Gohagan, John K.·2000·Controlled Clinical Trials
DOI 10.1016/s0197-2456(00)00098-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0197-2456(00)00098-2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 125

  1. Silverberg, 1989, Cancer statistics, 1989, CA Cancer J Clin, 39, 3, 10.3322/canjclin.39.1.3 · DOI · Paper page
  2. Gallion, 1989, Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer, Cancer, 63, 1070, 10.1002/1097-0142(19890315)63:6<1070::AID-CNCR2820630605>3.0.CO;2-F · doi:10.1002/1097-0142(19890315)63:6<1070::aid-cncr2820630605>3.0.co;2-f
  3. Gilbertsen, 1971, Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease, JAMA, 215, 81, 10.1001/jama.1971.03180140045007 · doi:10.1001/jama.1971.03180140045007
  4. Jenson, 1960, Evaluation of annual examinations in the detection of cancer, JAMA, 174, 1783, 10.1001/jama.1960.03030140005002 · doi:10.1001/jama.1960.03030140005002
  5. Chodak, 1984, Early detection of prostate cancer by routine screening, JAMA, 252, 3261, 10.1001/jama.1984.03350230021025 · doi:10.1001/jama.1984.03350230021025
  6. Chodak, 1989, Assessment of screening for prostate cancer using the digital rectal examination, J Urol, 141, 1136, 10.1016/S0022-5347(17)41192-X · doi:10.1016/s0022-5347(17)41192-x
  7. Cooner, 1988, Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer, J Urol, 139, 758, 10.1016/S0022-5347(17)42624-3 · doi:10.1016/s0022-5347(17)42624-3
  8. Babaian, 1992, The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project, Cancer, 69, 1195, 10.1002/cncr.2820690521 · doi:10.1002/cncr.2820690521
  9. Thompson, 1984, Adenocarcinoma of the prostate: Results of routine urological screening, J Urol, 132, 690, 10.1016/S0022-5347(17)49828-4 · doi:10.1016/s0022-5347(17)49828-4
  10. Thompson, 1987, Impact of routine screening for adenocarcinoma of the prostate on the stage distribution, J Urol, 137, 424, 10.1016/S0022-5347(17)44055-9 · doi:10.1016/s0022-5347(17)44055-9
  11. Thompson, 1991, Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate, Scand J Urol Nephrol, 25, 111, 10.3109/00365599109024543 · doi:10.3109/00365599109024543
  12. Friedman, 1991, Case-control study of screening for prostatic cancer by digital rectal examinations, Lancet, 337, 1526, 10.1016/0140-6736(91)93207-P · doi:10.1016/0140-6736(91)93207-p
  13. Chodak, 1989, Progress and problems in screening for carcinoma of the prostate, World J Surg, 13, 60, 10.1007/BF01671155 · DOI
  14. Chodak, 1986, Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer, J Urol, 135, 951, 10.1016/S0022-5347(17)45935-0 · doi:10.1016/s0022-5347(17)45935-0
  15. Clements, 1988, How accurate is the index finger? A comparison of digital and ultrasound examination of the prostatic nodule, Clin Radiol, 39, 87, 10.1016/S0009-9260(88)80352-0 · doi:10.1016/s0009-9260(88)80352-0
  16. Lee, 1988, Prostate cancer: Comparison of transrectal US and digital rectal examination for screening, Radiology, 168, 389, 10.1148/radiology.168.2.3293108 · DOI · Paper page
  17. Lee, 1989, Hypoechoic lesions of the prostate: Clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen, Radiology, 170, 29, 10.1148/radiology.170.1.2462262 · DOI · Paper page
  18. McClennan, 1988, Transrectal US of the prostate: Is the technology leading the science?, Radiology, 168, 571, 10.1148/radiology.168.2.3293115 · doi:10.1148/radiology.168.2.3293115
  19. Torp-Pedersen, 1988, Early prostate cancer: Diagnostic costs of screening transrectal US and digital rectal examination, Radiology, 169, 351, 10.1148/radiology.169.2.3140290 · doi:10.1148/radiology.169.2.3140290
  20. Waterhouse, 1989, The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma, J Urol, 141, 233, 10.1016/S0022-5347(17)40729-4 · doi:10.1016/s0022-5347(17)40729-4
  21. Lange, 1989, The value of serum prostate specific antigen determinations before and after radical prostatectomy, J Urol, 141, 873, 10.1016/S0022-5347(17)41037-8 · doi:10.1016/s0022-5347(17)41037-8
  22. Oesterling, 1988, Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy, J Urol, 139, 766, 10.1016/S0022-5347(17)42630-9 · DOI
  23. Stamey, 1987, Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, N Engl J Med, 317, 909, 10.1056/NEJM198710083171501 · DOI · Paper page
  24. Partin, 1994, The clinical usefulness of prostate specific antigen: Update, 1994, J Urol, 152, 1358, 10.1016/S0022-5347(17)32422-9 · DOI · Paper page
  25. Coley, 1997, Early detection of prostate cancer. Part 1: Prior probability and effectiveness of tests. The American College of Physicians, Ann Intern Med, 126, 394, 10.7326/0003-4819-126-5-199703010-00010 · doi:10.7326/0003-4819-126-5-199703010-00010
  26. Brawer, 1992, Screening for prostatic carcinoma with prostate specific antigen, J Urol, 147, 841, 10.1016/S0022-5347(17)37401-3 · DOI
  27. Catalona, 1991, Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, New Engl J Med, 324, 1156, 10.1056/NEJM199104253241702 · DOI · Paper page
  28. Carter, 1992, Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease, JAMA, 267, 2215, 10.1001/jama.1992.03480160073037 · DOI · Paper page
  29. Benson, 1992, Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer, J Urol, 147, 815, 10.1016/S0022-5347(17)37393-7 · DOI
  30. Kane, 1992, Prostate-specific antigen levels in 1695 men withoutevidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project, Cancer, 69, 1201, 10.1002/cncr.2820690522 · doi:10.1002/cncr.2820690522
  31. Oesterling, 1992, Prostate-specific antigen: Improving its ability to diagnose early prostate cancer, JAMA, 267, 2236, 10.1001/jama.1992.03480160094042 · DOI
  32. Lee, 1992, Predicted prostate specific antigen results usingtransrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer, Cancer, 70, 211, 10.1002/1097-0142(19920701)70:1+<211::AID-CNCR2820701307>3.0.CO;2-D · doi:10.1002/1097-0142(19920701)70:1+<211::aid-cncr2820701307>3.0.co;2-d
  33. Bangma, 1995, Volume adjustment for intermediate prostate-specific antigen values in a screening population, Eur J Cancer, 31A, 12, 10.1016/0959-8049(94)00309-S · doi:10.1016/0959-8049(94)00309-s
  34. Demura, 1993, Measurement of prostate specific antigen and gamma-seminoprotein ratio: A new means of distinguishing benign prostatic hyperplasia and prostate cancer, J Urol, 150, 1740, 10.1016/S0022-5347(17)35883-4 · doi:10.1016/s0022-5347(17)35883-4
  35. Lilja, 1993, Significance of different molecular forms of serum PSA. The free, non-complexed form of PSA versus that complexes to alpha 1-antichymotrypsin, Urol Clin North Am, 20, 681, 10.1016/S0094-0143(21)00920-4 · doi:10.1016/s0094-0143(21)00920-4
  36. Bangma, 1995, The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men, Urology, 46, 773, 10.1016/S0090-4295(99)80342-2 · doi:10.1016/s0090-4295(99)80342-2
  37. Vashi, 1997, Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system, Urology, 49, 19, 10.1016/S0090-4295(96)00511-0 · doi:10.1016/s0090-4295(96)00511-0
  38. Cooner, 1990, Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen, J Urol, 43, 1146, 10.1016/S0022-5347(17)40211-4 · DOI · Paper page
  39. Johansson, 1989, Natural history of localised prostatic cancer. A population-based study in 223 untreated patients, Lancet, 1, 799, 10.1016/S0140-6736(89)92269-1 · doi:10.1016/s0140-6736(89)92269-1
  40. Miller, 1989, Histopathology of prostate cancer: Prediction of malignant behavior and correlation with ultrasonography, Urology, 33, 18, 10.1016/S0090-4295(89)80004-4 · doi:10.1016/s0090-4295(89)80004-4
  41. Kramer, 1993, Prostate cancer screening: What we know and what we need to know, Ann Intern Med, 119, 914, 10.7326/0003-4819-119-9-199311010-00009 · DOI · Paper page
  42. Chodak, 1994, Results of conservative management of clinically localized prostate cancer, New Engl J Med, 330, 242, 10.1056/NEJM199401273300403 · DOI · Paper page
  43. Fleming, 1993, A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team, JAMA, 269, 2650, 10.1001/jama.269.20.2650 · doi:10.1001/jama.269.20.2650 · Paper page
  44. Barry, 1995, Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program, Urology, 46, 445, 10.1016/S0090-4295(99)80255-6 · doi:10.1016/s0090-4295(99)80255-6
  45. Beck, 1994, Acritique of the decision analysis for clinically localized prostate cancer, J Urol, 152, 1894, 10.1016/S0022-5347(17)32409-6 · DOI
  46. Lu-Yao, 1997, Population-based study of long-term survival in patients with clinically localised prostate cancer, Lancet, 349, 906, 10.1016/S0140-6736(96)09380-4 · DOI · Paper page
  47. Prestigiacomo, 1996, Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers, J Urol, 155, 1977, 10.1016/S0022-5347(01)66067-1 · doi:10.1016/s0022-5347(01)66067-1
  48. Schroder, 1997, The European randomized study of screening for prostate cancer (ERSPC), Br J Urol, 79, 68, 10.1111/j.1464-410X.1997.tb00804.x · doi:10.1111/j.1464-410x.1997.tb00804.x
  49. Auvinen, 1996, Prospective evaluation plan for randomized trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group, J Med Screen, 3, 97, 10.1177/096914139600300211 · DOI
  50. Boucot, 1973, Is curable lung cancer detected by semiannual screening, JAMA, 224, 1361, 10.1001/jama.1973.03220240015004 · doi:10.1001/jama.1973.03220240015004
  51. Lilienfeld, 1966, An evaluation of radiologic and cytologic screening for the early detection of lung cancer: A cooperative pilot study of the American Cancer Society and the Veterans Administration, Cancer Res, 26, 2083
  52. Nash, 1968, South London lung cancer study, Br Med J, 2, 715, 10.1136/bmj.2.5607.715 · DOI
  53. Brett, 1968, The value of lung cancer detection by six-monthly chest radiographs, Thorax, 23, 414, 10.1136/thx.23.4.414 · doi:10.1136/thx.23.4.414
  54. Brett, 1969, Earlier diagnosis and survival in lung cancer, Br Med J, 4, 260, 10.1136/bmj.4.5678.260 · DOI · Paper page
  55. Dales, 1979, Evaluating periodic multiphasic health check-ups: A controlled trial, J Chronic Dis, 32, 385, 10.1016/0021-9681(79)90080-8 · DOI
  56. Friedman, 1986, Multiphasic health checkup evaluation: A 16-year follow-up, J Chronic Dis, 39, 453, 10.1016/0021-9681(86)90112-8 · DOI · Paper page
  57. Cole, 1980, Basic issues in population screening for cancer, J Natl Cancer Inst, 64, 1263
  58. Prorok, 1986, Screening for the early detection of cancer, Cancer Invest, 4, 225, 10.3109/07357908609018453 · DOI
  59. Kubik, 1986, Lung cancer detection. Results of a randomized prospective study in Czechoslovakia, Cancer, 57, 2427, 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M · DOI · Paper page
  60. Kubik, 1990, Lack of benefit from semi-annual screening for cancer of the lung: Follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia, Int J Cancer, 45, 26, 10.1002/ijc.2910450107 · DOI · Paper page
  61. Ebeling, 1987, Screening for lung cancer—Results from a case-control study, Int J Cancer, 40, 141, 10.1002/ijc.2910400202 · doi:10.1002/ijc.2910400202
  62. Sobue, 1992, A case-control study for evaluating lung-cancer screening in Japan. Japanese Lung-Cancer Screening Group, Int J Cancer, 50, 230, 10.1002/ijc.2910500212 · DOI
  63. Levin, 1982, Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: A preliminary report, Recent Results Cancer Res, 82, 138, 10.1007/978-3-642-81768-7_13 · doi:10.1007/978-3-642-81768-7_13
  64. Stitik, 1978, Radiographic screening in the early detection of lung cancer, Radiol Clin North Am, 16, 347
  65. Melamed, 1981, Detection of true pathologic stage I lung cancer in a screening program and the effect on survival, Cancer, 47, 1182, 10.1002/1097-0142(19810301)47:5+<1182::AID-CNCR2820471322>3.0.CO;2-4 · doi:10.1002/1097-0142(19810301)47:5+<1182::aid-cncr2820471322>3.0.co;2-4
  66. Melamed, 1984, Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York, Chest, 44, 10.1378/chest.86.1.44 · DOI · Paper page
  67. Flehinger, 1987, The natural history of lung cancer in a periodically screened population, Biometrics, 43, 127, 10.2307/2531955 · doi:10.2307/2531955
  68. Flehinger, 1988, Natural history of adenocarcinoma-large cell carcinoma of the lung: Conclusions from screening programs in New York and Baltimore, J Natl Cancer Inst, 80, 337, 10.1093/jnci/80.5.337 · doi:10.1093/jnci/80.5.337
  69. Shukla, 1989, Survival benefits of x-ray screening for lung cancer after bias adjustments, Computers and Mathematics with Applications, 18, 937, 10.1016/0898-1221(89)90012-6 · doi:10.1016/0898-1221(89)90012-6
  70. Winawer, 1980, Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia, Cancer, 45, 2959, 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E · doi:10.1002/1097-0142(19800615)45:12<2959::aid-cncr2820451212>3.0.co;2-e
  71. Selby, 1993, Effect of fecal occultblood testing on mortality from colorectal cancer. A case-control study, Ann Intern Med, 118, 1, 10.7326/0003-4819-118-1-199301010-00001 · DOI · Paper page
  72. Lazovich, 1995, A case-control study to evaluate efficacy of screening for faecal occult blood, J Med Screen, 2, 84, 10.1177/096914139500200206 · doi:10.1177/096914139500200206
  73. Winawer, 1993, Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy, J Natl Cancer Inst, 85, 1311, 10.1093/jnci/85.16.1311 · DOI · Paper page
  74. Mandel, 1993, Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N Eng J Med, 328, 1365, 10.1056/NEJM199305133281901 · DOI · Paper page
  75. Hardcastle, 1996, Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 348, 1472, 10.1016/S0140-6736(96)03386-7 · DOI · Paper page
  76. Kewenter, 1988, Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects, Cancer, 62, 645, 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-# · doi:10.1002/1097-0142(19880801)62:3<645::aid-cncr2820620333>3.0.co;2-#
  77. Kronborg, 1987, Initial mass screening for colorectal cancer with fecal occult blood test, Scand J Gastroenterol, 22, 677, 10.3109/00365528709011142 · doi:10.3109/00365528709011142
  78. Kronborg, 1989, Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark, Scand J Gastroenterol, 24, 599, 10.3109/00365528909093096 · DOI
  79. Kronborg, 1996, Randomized study of screening for colorectal cancer with faecal-occult-blood test, Lancet, 348, 1467, 10.1016/S0140-6736(96)03430-7 · DOI · Paper page
  80. 1980, Guidelines for the cancer-related checkup: Recommendations and rationale, CA Cancer J Clin, 30, 194, 10.3322/canjclin.30.4.194 · doi:10.3322/canjclin.30.4.194
  81. Selby, 1988, Sigmoidoscopy and mortality from colorectal cancer: The Kaiser Permanente Multiphasic Evaluation Study, J Clin Epidemiol, 41, 427, 10.1016/0895-4356(88)90043-1 · doi:10.1016/0895-4356(88)90043-1
  82. Herrinton, 1995, Case-control study of digital rectal screening in relation to mortality from cancer of the distal rectum, Am J Epidemiol, 142, 961, 10.1093/oxfordjournals.aje.a117744 · DOI
  83. Gilbertsen, 1974, Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer, Cancer, 34, 936, 10.1002/1097-0142(197409)34:3+<936::AID-CNCR2820340722>3.0.CO;2-5 · doi:10.1002/1097-0142(197409)34:3+<936::aid-cncr2820340722>3.0.co;2-5
  84. Gilbertsen, 1978, The prevention of invasive cancer of the rectum, Cancer, 41, 1137, 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G · DOI · Paper page
  85. Hertz, 1960, Value of periodic examinations in detecting cancer of the colon and rectum, Postgrad Med, 27, 290, 10.1080/00325481.1960.11712835 · doi:10.1080/00325481.1960.11712835
  86. Crespi, 1984, The role of proctosigmoidoscopy in screening for colorectal neoplasia, CA Cancer J Clin, 34, 158, 10.3322/canjclin.34.3.158 · doi:10.3322/canjclin.34.3.158
  87. Winawer, 1987, Patient response to sigmoidoscopy. A randomized, controlled trial of rigid and flexible sigmoidoscopy, Cancer, 60, 1905, 10.1002/1097-0142(19871015)60:8<1905::AID-CNCR2820600839>3.0.CO;2-K · DOI
  88. Winawer, 1993, Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup, New Eng J Med, 329, 1977, 10.1056/NEJM199312303292701 · DOI · Paper page
  89. Chamberlain, 1986, UICC workshop of the Project on Evaluation of Screening Programmes for Gastrointestinal Cancer, Int J Cancer, 37, 329, 10.1002/ijc.2910370302 · doi:10.1002/ijc.2910370302
  90. Neugut, 1988, Role of sigmoidoscopy in screening for colorectal cancer: A critical review, Gastroenterology, 95, 492, 10.1016/0016-5085(88)90511-2 · DOI
  91. Eddy, 1987, Screening for colorectal cancer in a high-risk population. Results of a mathematical model, Gastroenterology, 92, 682, 10.1016/0016-5085(87)90018-7 · doi:10.1016/0016-5085(87)90018-7
  92. Eddy, 1990, Screening for colorectal cancer, Ann Intern Med, 113, 373, 10.7326/0003-4819-113-5-373 · DOI · Paper page
  93. Newcomb, 1992, Screening sigmoidoscopy and colorectal cancer mortality, J Natl Cancer Inst, 84, 1572, 10.1093/jnci/84.20.1572 · DOI · Paper page
  94. Selby, 1992, A case-control study of screening sigmoidoscopy and mortality from colorectal cancer, N Engl J Med, 326, 653, 10.1056/NEJM199203053261001 · DOI · Paper page
  95. Granberg, 1989, Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation, Gynecol Oncol, 35, 139, 10.1016/0090-8258(89)90031-0 · DOI · Paper page
  96. Jacobs, 1989, The CA 125 tumour-associated antigen: A review of the literature, Hum Reprod, 4, 1, 10.1093/oxfordjournals.humrep.a136832 · DOI · Paper page
  97. Einhorn, 1992, Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer, Obstet Gynecol, 80, 14
  98. Helzlsouer, 1993, Prospective study of serum CA-125 levels as markers of ovarian cancer, JAMA, 269, 1123, 10.1001/jama.1993.03500090059033 · DOI
  99. Zurawski, 1988, Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer, Int J Cancer, 42, 677, 10.1002/ijc.2910420507 · DOI · Paper page
  100. Higgins, 1990, Interobserver variation in ovarian measurements using transvaginal sonography, Gynecol Oncol, 39, 69, 10.1016/0090-8258(90)90401-6 · doi:10.1016/0090-8258(90)90401-6
  101. van Nagell, 1990, Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened, Cancer, 65, 573, 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4 · doi:10.1002/1097-0142(19900201)65:3<573::aid-cncr2820650331>3.0.co;2-4
  102. Andolf, 1990, Ultrasound examination for detection of ovarian carcinoma in risk groups, Obstet Gynecol, 75, 106
  103. Campbell, 1989, Transabdominal ultrasound screening for early ovarian cancer, BMJ, 299, 1363, 10.1136/bmj.299.6712.1363 · DOI · Paper page
  104. DePriest, 1993, Ovarian cancer screening in asymptomatic postmenopausal women, Gynecol Oncol, 51, 205, 10.1006/gyno.1993.1273 · doi:10.1006/gyno.1993.1273
  105. Bourne, 1993, Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging, BMJ, 306, 1025, 10.1136/bmj.306.6884.1025 · DOI · Paper page
  106. Freedman, 1990, Statistical designs for investigating several interventions in the same study: Methods for cancer prevention trials, J Natl Cancer Inst, 82, 910, 10.1093/jnci/82.11.910 · doi:10.1093/jnci/82.11.910
  107. Etzioni, 1995, Design and analysis of cancer screening trials, Stat Methods Med Res, 4, 3, 10.1177/096228029500400102 · DOI
  108. Tabar, 1992, Update of the Swedish two-county program of mammographic screening for breast cancer, Radiologic Clin North Am, 30, 187, 10.1016/S0033-8389(22)02494-0 · DOI · Paper page
  109. Simpson, 2000, Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first six years, Control Clin Trials, 21, 356S, 10.1016/S0197-2456(00)00102-1 · doi:10.1016/s0197-2456(00)00102-1
  110. Hayes, 2000, Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 349S, 10.1016/S0197-2456(00)00101-X · DOI · Paper page
  111. Weissfeld, 2000, Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 390S, 10.1016/S0197-2456(00)00094-5 · doi:10.1016/s0197-2456(00)00094-5
  112. Miller, 2000, Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 400S, 10.1016/S0197-2456(00)00095-7 · doi:10.1016/s0197-2456(00)00095-7
  113. Taylor, 1972, Biometric design of the Mayo Lung Project for early detection and localization of bronchogenic carcnoma, Cancer, 30, 1344, 10.1002/1097-0142(197211)30:5<1344::AID-CNCR2820300530>3.0.CO;2-6 · DOI
  114. Dunnett, 1996, An alternative to the use of two-sided tests in clinical trials, Stat Med, 15, 1729, 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
  115. Brown, 1990, The knowledge and use of screening tests for colorectal and prostate cancer:Data from the 1987 National Health Interview survey, Prev Med, 19, 562, 10.1016/0091-7435(90)90054-N · doi:10.1016/0091-7435(90)90054-n
  116. Polednak, 1990, Knowledge of colorectal cancer and use of screening tests in persons 40–74 years of age, Prev Med, 19, 213, 10.1016/0091-7435(90)90022-C · DOI
  117. Hasson, 2000, Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 329S, 10.1016/S0197-2456(00)00100-8 · DOI
  118. Day, 1985, Estimating the sensitivity of a screening test, J Epidemiol Community Health, 39, 364, 10.1136/jech.39.4.364 · DOI
  119. Day, 1984, Simplified models of screening for chronic disease: Estimation procedures from mass screening programs, Biometrics, 40, 1, 10.2307/2530739 · DOI · Paper page
  120. Walter, 1983, Estimation of the duration of a pre-clinical state using screening data, Am J Epidemiol, 11, 865, 10.1093/oxfordjournals.aje.a113705 · doi:10.1093/oxfordjournals.aje.a113705
  121. Kafadar, 1994, A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials, Stat Med, 13, 569, 10.1002/sim.4780130519 · DOI
  122. Kafadar, 1997, Estimating the difference in location parameters of two survival curves, with applications to cancer screening, J Statist Planning Interference, 57, 165, 10.1016/S0378-3758(96)00042-0 · doi:10.1016/s0378-3758(96)00042-0
  123. Day, 1989, Breast cancer screening programmes: The development of a monitoring and evaluation system, Br J Cancer, 59, 954, 10.1038/bjc.1989.203 · doi:10.1038/bjc.1989.203
  124. Lan, 1989, Group sequential procedures: Calendar versus information time, Stat Med, 8, 1191, 10.1002/sim.4780081003 · DOI · Paper page
  125. Lin, 1999, A general theory on stochastic curtailment for censored survival data, J Am Stat Assoc, 94, 510, 10.2307/2670171 · doi:10.2307/2670171

Cited by

See all 1,037

Metadata

Authors
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., Hayes, R. B., Johnson, C. C., Mandel, J. S., Oberman, A., O'Brien, B., Oken, M. M., Rafla, S., Reding, D., Rutt, W., Weissfeld, J. L., Yokochi, L., & Gohagan, J. K.
Venue
Controlled Clinical Trials
Publisher
Elsevier BV
Published
2000-12
Volume
21
Issue
6
Pages
273S-309S
ISSN
0197-2456 (ISSN-L)
DOI
10.1016/s0197-2456(00)00098-2
OpenAlex
W1973198827
Cited by
1,037
References
0
FWCI
7.16
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. https://app.cochat.ai/papers/10.1016/s0197-2456(00)00098-2
The paper
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., Hayes, R. B., Johnson, C. C., Mandel, J. S., Oberman, A., O'Brien, B., Oken, M. M., Rafla, S., Reding, D., Rutt, W., . . . Gohagan, J. K. (2000). Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Controlled Clinical Trials. https://doi.org/10.1016/s0197-2456(00)00098-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.